Krabeva 100mg Injection
Marketer
Biocon
Salt Composition
Bevacizumab (100mg)
Overview Krabeva 100mg Injection
Oncaspar 100mg Injection is a cancer treatment medication. Indicated for colorectal cancer, non-small cell lung cancer, renal cell carcinoma, brain tumors, and gynecological cancers (ovarian and cervical), it functions by inhibiting tumor angiogenesis, thereby hindering tumor growth. This effective medication is often a first-line treatment when combined with other chemotherapeutic agents. Administered intravenously via infusion (through a vein or implanted port), dosage and treatment length are determined by your physician, who will also monitor for infusion reactions like hypertension and respiratory distress. Continued use depends on disease control and manageable side effects, with discontinuation decided by your doctor. Regular monitoring of blood pressure and urinary protein levels may be recommended. Common side effects include rectal hemorrhage, altered taste perception, and cephalalgia. Pre-surgical notification to your surgeon is crucial due to Oncaspar's potential to impair wound healing and increase bleeding risk; report any unusual bleeding immediately. Disclose current pregnancies, pregnancy plans, or breastfeeding to your physician. Comprehensive disclosure of all other medications to your healthcare provider is essential due to potential drug interactions.
Uses of Krabeva 100mg Injection
Colorectal cancer, ovarian neoplasm, cervical carcinoma, renal cell carcinoma, brain cancer, and non-small cell lung carcinoma.
Major Benefits of Krabeva 100mg Injection:
The medication will be administered by your physician or their designated nurse; self-medication is strictly prohibited.
Common Side effects of Krabeva 100mg Injection:
- Exfoliative dermatitis
- High blood pressure
- Nosebleeds
- Protein in urine
- Decreased appetite
- Electrolyte imbalance
- Peripheral sensory neuropathy
- Breathlessness
- Thromboembolism
- Wound healing complications
- Ovarian failure
- Decreased white blood cell count (lymphocytes)
- Low blood platelets
- Mucosal inflammation
- Abscess
- Cellulitis
- Hypersensitivity
- Rectovaginal fistula
How to use Krabeva 100mg Injection:
This medication will be administered by your healthcare provider. Self-medication is strictly prohibited.
How Krabeva 100mg Injection works:
Krabeva 100mg Injection is an anti-angiogenesis agent. Its mechanism involves VEGF inhibition, thus preventing the growth of blood vessels supplying tumors with essential oxygen and nutrients.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Krabeva 100mg Injection may pose unknown risks. Seek medical advice before combining them.
PregnancyCONSULT YOUR DOCTOR
The use of Krabeva 100mg Injection during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible hazards prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Administering Krabeva 100mg Injection while breastfeeding is likely inadvisable. Available human data indicates potential transfer to breast milk, posing a possible risk to the infant.
DrivingUNSAFE
Administration of Krabeva 100mg Injection may induce adverse reactions impacting driving capabilities. Reported side effects associated with Krabeva 100mg Injection include drowsiness and syncope, potentially compromising driving safety.
KidneySAFE IF PRESCRIBED
The use of Krabeva 100mg Injection in individuals with kidney impairment appears to pose minimal risk. Preliminary findings indicate dose modification may be unnecessary; however, physician consultation is recommended.
LiverSAFE IF PRESCRIBED
The use of Krabeva 100mg Injection in individuals with hepatic impairment is likely safe. Available evidence indicates dose modification may be unnecessary; however, physician consultation is recommended.
What if you forget to take Krabeva 100mg Injection :
Omit a dose of Krabeva 100mg Injection? Seek your physician's advice.
Facts to Know About Krabeva 100mg Injection
| Label | Value |
|---|---|
| Chemical Type | Monoclonal antibody |
| Developing Habits | No. |
| Treatment Category | Cancer Therapeutics |
| Action Class | VEGF inhibitor |
3,018 People bought this recently